Sarepta Therapeutics Inc

SRPT remains in a Stage 4 decline with a clear sequence of lower highs and lower lows and EMAs rejecting price rallies. Medium-term bias is bearish, and short-term conditions favor further downside as price fails at EMA and 50 DMA resistance. Execution is Sell Now on rallies into the EMA/50 DMA zone to participate in ongoing downtrend momentum.

• ↑Q1 net product revenue hit $331M, targeting $1.2–1.4B in 2026 guidance.
• ↑$748M cash position funds R&D and siRNA pipeline without dilution.
• ↓Negative profitability metrics and earnings yield highlight efficiency challenges.